← All trials
NCT06411249
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 4, 2024
- Primary completion
- Apr 19, 2027
- Completion date
- May 29, 2029
- First posted
- May 13, 2024
- Last posted
- Jun 3, 2024
- Enrollment
- 350
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.